ALX Oncology (NASDAQ:ALXO) Trading 6.5% Higher

ALX Oncology Holdings Inc. (NASDAQ:ALXOGet Free Report)’s share price was up 6.5% during trading on Wednesday . The stock traded as high as $15.67 and last traded at $15.43. Approximately 184,696 shares traded hands during mid-day trading, a decline of 55% from the average daily volume of 406,349 shares. The stock had previously closed at $14.49.

Wall Street Analysts Forecast Growth

Several analysts have commented on ALXO shares. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of ALX Oncology in a research note on Wednesday, April 10th. Cantor Fitzgerald reissued an “overweight” rating on shares of ALX Oncology in a report on Friday, April 12th. Finally, Stifel Nicolaus reissued a “hold” rating and issued a $14.00 price target (up previously from $10.00) on shares of ALX Oncology in a report on Friday, March 8th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $18.83.

View Our Latest Analysis on ALXO

ALX Oncology Price Performance

The firm has a market cap of $789.36 million, a PE ratio of -4.20 and a beta of 1.58. The stock’s fifty day moving average price is $13.55 and its 200-day moving average price is $11.90. The company has a debt-to-equity ratio of 0.05, a current ratio of 5.24 and a quick ratio of 5.24.

ALX Oncology (NASDAQ:ALXOGet Free Report) last released its earnings results on Thursday, March 7th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.09). As a group, equities analysts expect that ALX Oncology Holdings Inc. will post -3.33 EPS for the current fiscal year.

Insider Activity

In other news, CEO Jason Lettmann purchased 4,400 shares of the stock in a transaction dated Thursday, March 14th. The shares were purchased at an average price of $11.31 per share, with a total value of $49,764.00. Following the transaction, the chief executive officer now owns 171,620 shares in the company, valued at approximately $1,941,022.20. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, CEO Jason Lettmann purchased 4,400 shares of the stock in a transaction dated Thursday, March 14th. The shares were purchased at an average price of $11.31 per share, with a total value of $49,764.00. Following the transaction, the chief executive officer now owns 171,620 shares in the company, valued at approximately $1,941,022.20. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Jaume Pons sold 20,000 shares of the business’s stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $11.15, for a total transaction of $223,000.00. Following the transaction, the insider now directly owns 628,359 shares in the company, valued at approximately $7,006,202.85. The disclosure for this sale can be found here. Corporate insiders own 50.30% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Legal & General Group Plc lifted its position in ALX Oncology by 42.6% in the fourth quarter. Legal & General Group Plc now owns 2,289 shares of the company’s stock valued at $34,000 after buying an additional 684 shares during the last quarter. Credit Suisse AG increased its stake in ALX Oncology by 6.6% during the second quarter. Credit Suisse AG now owns 15,157 shares of the company’s stock worth $121,000 after purchasing an additional 940 shares during the period. American International Group Inc. increased its stake in shares of ALX Oncology by 14.1% during the second quarter. American International Group Inc. now owns 10,040 shares of the company’s stock worth $81,000 after buying an additional 1,237 shares during the period. Swiss National Bank increased its stake in shares of ALX Oncology by 8.5% during the first quarter. Swiss National Bank now owns 19,200 shares of the company’s stock worth $324,000 after buying an additional 1,500 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of ALX Oncology during the fourth quarter worth approximately $28,000. Institutional investors and hedge funds own 97.97% of the company’s stock.

ALX Oncology Company Profile

(Get Free Report)

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.

See Also

Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.